AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating restated by Cowen and Company in a research report issued to clients and investors on Thursday.

Other analysts have also issued reports about the company. ValuEngine lowered AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. BidaskClub upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Citigroup Inc. lowered their price objective on AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a research report on Friday, July 7th. Barclays PLC reiterated a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a research report on Monday, May 15th. Finally, Zacks Investment Research lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $28.09.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 17.50 on Thursday. The firm has a 50-day moving average of $19.12 and a 200-day moving average of $20.89. The firm’s market capitalization is $613.29 million. AMAG Pharmaceuticals has a one year low of $16.00 and a one year high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.18. The firm had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The company’s revenue was up 24.3% on a year-over-year basis. During the same period last year, the company earned $1.45 earnings per share. On average, equities analysts predict that AMAG Pharmaceuticals will post ($0.41) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/10/amag-pharmaceuticals-inc-amag-receives-hold-rating-from-cowen-and-company.html.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the transaction, the senior vice president now owns 28,336 shares in the company, valued at $566,720. The sale was disclosed in a document filed with the SEC, which is available through this link. 3.80% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of AMAG. BlackRock Inc. boosted its position in shares of AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after buying an additional 4,988,054 shares during the period. Acadian Asset Management LLC boosted its position in AMAG Pharmaceuticals by 777.8% in the first quarter. Acadian Asset Management LLC now owns 1,226,690 shares of the specialty pharmaceutical company’s stock valued at $27,659,000 after buying an additional 1,086,937 shares during the period. State Street Corp boosted its position in AMAG Pharmaceuticals by 75.2% in the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock valued at $56,876,000 after buying an additional 1,082,366 shares during the period. Dimensional Fund Advisors LP boosted its position in AMAG Pharmaceuticals by 152.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock valued at $23,129,000 after buying an additional 619,370 shares during the period. Finally, Perceptive Advisors LLC boosted its position in AMAG Pharmaceuticals by 2,768.3% in the first quarter. Perceptive Advisors LLC now owns 560,000 shares of the specialty pharmaceutical company’s stock valued at $12,628,000 after buying an additional 540,476 shares during the period.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.